Home/Filings/3/0001209191-20-025500
3//SEC Filing

COLUMN GROUP II, LP 3

Accession 0001209191-20-025500

CIK 0001796280other

Filed

Apr 22, 8:00 PM ET

Accepted

Apr 23, 8:43 PM ET

Size

11.8 KB

Accession

0001209191-20-025500

Insider Transaction Report

Form 3
Period: 2020-04-23
Holdings
  • Common Stock

    75,000
  • Series B Preferred Stock

    Common Stock (625,000 underlying)
  • Series A Preferred Stock

    Common Stock (3,500,000 underlying)
  • Series C Preferred Stock

    Common Stock (416,666 underlying)
  • Series D Preferred Stock

    Common Stock (151,515 underlying)
Holdings
  • Series C Preferred Stock

    Common Stock (416,666 underlying)
  • Series A Preferred Stock

    Common Stock (3,500,000 underlying)
  • Series D Preferred Stock

    Common Stock (151,515 underlying)
  • Common Stock

    75,000
  • Series B Preferred Stock

    Common Stock (625,000 underlying)
GOEDDEL DAVID V
10% OwnerOther
Holdings
  • Series B Preferred Stock

    Common Stock (625,000 underlying)
  • Series D Preferred Stock

    Common Stock (151,515 underlying)
  • Common Stock

    75,000
  • Series A Preferred Stock

    Common Stock (3,500,000 underlying)
  • Series C Preferred Stock

    Common Stock (416,666 underlying)
Footnotes (2)
  • [F1]The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
  • [F2]The number of shares of Common Stock reflects a 1-for-4 reverse stock split of the Issuer's Common Stock and Preferred Stock which became effective April 21, 2020. Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock, for no additional consideration, and has no expiration date.

Issuer

Oric Pharmaceuticals, Inc.

CIK 0001796280

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001600420

Filing Metadata

Form type
3
Filed
Apr 22, 8:00 PM ET
Accepted
Apr 23, 8:43 PM ET
Size
11.8 KB